Table 2. Changes in N-QoL scores after 12 weeks treatment with prosultiamine

	Pretreatment	Posttreatment	P***
Q1 Concentration	0.6 ± 1.0	0.3 ± 1.6	0.1235
Q2 Low in energy	0.9 ± 1.1	0.4 ± 0.6	0.0077
Q3 Sleep during the day	1.5 ± 1.4	1.0 ± 1.1	0.0229
Q4 Productiveness	0.7 ± 0.9	0.3 ± 0.6	0.0830
Q5 Physical activities	1.0 ± 1.2	0.5 ± 0.8	0.0505
Q6 Fluid restriction	0.8 ± 1.2	0.7 ± 0.9	0.3270
Q7 Inadequate sleep at night	1.6 ± 1.5	0.7 ± 1.0	0.0070
Q8 Disturbance of others	0.8 ± 1.9	0.5 ± 1.8	0.0277
Q9 Preoccupation with waking at nigh	0.6 ± 1.1	0.3 ± 0.6	0.1235
Q10 Worry over condition worseni	1.5 ± 1.5	0.8 ± 1.1	0.0032
Q11 Worried over treatment options	1.5 ± 1.6	1.0 ± 1.3	0.0303
Q12 Overall bother	1.3 ± 1.3	0.8 ± 0.8	0.0238
Q13 Overall impact on everyday life	2.6 ± 2.8	0.9 ± 1.0	0.0023
Converted Overall Score(Q1-12)*	73.2 ± 21.0	85.3 ± 19.9	0.0001
Subscale Scores**			
Sleep/ Energy(Q1-5, 7)	74.0 ± 20.7	87.0 ± 15.0	0.0001
Bother/ Concern (Q6, Q8-12)	72.4 ± 25.7	83.7 ± 21.2	0.0028

Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire [15-17].

 $Converted\ overall\ score(0-100)=100\times total\ converted\ scores(Q1-12)/4\times question\ numbers,\ converted\ score=4-each\ raw\ score.$

 $^{^*}$ The scores ranges of each Question exception Q13 are from 0 to 4. The score of Q13 is from 0 to 10.

^{**} Subscale score(0-10)=100×total converted scores/4×question numbers.

^{***}Statistical significance was determined by the Wilcoxon signed-rank test.